Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review.
BMC Neurol
; 23(1): 286, 2023 Jul 31.
Article
em En
| MEDLINE
| ID: mdl-37525104
ABSTRACT
BACKGROUND:
As a modulator of the sphingosine 1-phosphate receptor, siponimod is administered as a therapeutic intervention for multiple sclerosis. A previous phase 3 study first reported siponimod-associated macular edema. Since that report, there were only few relevant reports in clinical settings. Here, we report a case of secondary progressive multiple sclerosis developed macular edema after siponimod treatment. We also review the progress of sphingosine 1-phosphate receptor modulators, elaborate on accepted mechanisms in treating multiple sclerosis, and discuss the causation of siponimod-associated macular edema. CASE PRESENTATION A 38-year-old Chinese female patient with secondary progressive multiple sclerosis, who had recurrent numbness of the limbs and right leg fatigue, developed mild macular edema following 4 months of siponimod treatment. The macular edema resolved after discontinuing the medication, and did not recur after resuming siponimod.CONCLUSION:
Although siponimod-associated macular edema may be rare, mild, transitory, and manageable, it cannot be ignored and requires ongoing vigilance.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Edema Macular
/
Esclerose Múltipla Crônica Progressiva
/
Esclerose Múltipla
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article